Novartis announces EU approval of Mayzent (siponimod) for adult patients with SPMS with active…
Novartis announced the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active…
Read More...
Read More...
